Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia

ClinicalTrials.gov Identifier: NCT05285540. First Posted : March 17, 2022 

The purpose of this study Phase 1 is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of intravenous DT-216 in adult patients with Friedreich Ataxia. This single ascending dose study is randomized, double-blind, placebo-controlled.

A Phase 1a, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of DT-216 in Adult Patients With Friedreich Ataxia